Physician profile

Thomas Curtis Namey

Rheumatology · Knoxville, TN

NPI 1023172608

$1,986.66

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

See the full distribution for Rheumatology

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $697.45 2019-2022
Lilly USA, LLC $477.87 2019-2021
Regeneron Healthcare Solutions, INC. $160.48 2019
E.R. Squibb & Sons, L.L.C. $111.06 2019-2020
Celgene Corporation $104.18 2019
Glaxosmithkline, LLC. $97.85 2019-2020
Abbvie INC. $69.04 2019-2020
Pfizer INC. $51.36 2019-2020
Horizon Therapeutics Plc $36.92 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $34.04 2020
Genzyme Corporation $30.73 2020
Mallinckrodt Enterprises LLC $30.62 2019
Zyla Life Sciences, INC. $28.72 2019
Amgen INC. $24.12 2019
Boehringer Ingelheim Pharmaceuticals, INC. $17.30 2019
Show all 16 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $14.92 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Curtis Namey

$1,986.66

in general payments reported 2019-2025

Years
2019-2022
Top company
Janssen Biotech, INC.

https://glasscript.com/doctor/182232/thomas-curtis-namey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.